Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic

Published: Thursday, February 27, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.

The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

The p53 protein is a sequence-specific transcription factor that functions as a major tumor suppressor in mammals. Inactivation of the tumor-suppressor function of p53 is one of the most frequent genetic alterations in human cancer, and close to half of all human tumors carry p53 gene mutations within their cells.

The patent discloses the finding that miR-34a, which is a direct transcriptional target of p53, possesses anti-proliferative and pro-apoptotic activities, thereby contributing to the tumor suppressor effects of activated p53. Overexpression of miR-34a exerts anti-proliferative effects and promotes cell death, whereas inactivation of miR-34a attenuates p53-mediated cell death. Thus, miR-34a is a direct transcriptional target of p53, which may mediate some of the biological effects of this tumor suppressor. Perturbation of miR-34a expression may thus contribute to tumorigenesis.

"We continue to fortify our leading intellectual property position in microRNA technology and these newly allowed patent claims expand, strengthen and complement our growing portfolio of over 35 patents worldwide," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "This patent is important as it protects key elements of our microRNA technology to develop oncology treatments for NSCLC in p53 negative patients and offers opportunities for monetization. With RNA-based therapeutics, including microRNA-targeting agents, continuing to progress in and towards the clinic, this patent allowance should create opportunities for us to exploit this important new piece of intellectual property. It also supports our broader oncology strategy to develop and commercialize microRNA-based diagnostics, therapeutics and biomarkers that will enhance clinicians' ability to identify and treat cancers."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Potential for microRNAs to Determine Risk of Recurrence in Colorectal Cancer
Rosetta Genomics, Ltd. announced the study has been published in the online edition of the International Journal of Oncology and is expected to appear in the upcoming print edition.
Tuesday, March 20, 2012
Rosetta Genomics Sells Ownership in Rosetta Green
The diagnostics developer announced that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held.
Monday, December 19, 2011
Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests
Rosetta Genomics, a leading developer and provider of microRNA-based molecular diagnostics, have been issued with a Clinical Laboratory Permit by the New York State Department of Health.
Tuesday, January 04, 2011
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
MicroRNA-based molecular diagnostics to mark Prometheus' entry into oncology market; Rosetta to receive R&D funding plus future royalties.
Tuesday, April 14, 2009
Rosetta Genomics Reports In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
Study shows a two-fold decrease in tumor-mass and suppression of the targeted MicroRNA.
Monday, February 16, 2009
Rosetta Genomics Announces Three new Diagnostic Tests to Enter Development
Tests include response prediction to ovarian cancer treatment, predicting gastric cancer recurrence risk, and differentiation of small cell from non-small cell lung cancer.
Friday, June 20, 2008
Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Both parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify microRNA biomarkers that have diagnostic and prognostic potential.
Tuesday, January 15, 2008
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!